Eli Chan

Author PubWeight™ 52.47‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Herb-drug interactions: a literature review. Drugs 2005 2.59
2 Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 2005 1.75
3 St. John's wort attenuates irinotecan-induced diarrhea via down-regulation of intestinal pro-inflammatory cytokines and inhibition of intestinal epithelial apoptosis. Toxicol Appl Pharmacol 2006 1.60
4 Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab 2008 1.29
5 Drug bioactivation, covalent binding to target proteins and toxicity relevance. Drug Metab Rev 2005 1.17
6 Pharmacokinetic interactions of drugs with St John's wort. J Psychopharmacol 2004 1.15
7 Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab 2004 1.15
8 Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J 2009 1.08
9 Human multidrug resistance associated protein 4 confers resistance to camptothecins. Pharm Res 2005 1.01
10 Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells. Mol Cancer Ther 2009 0.98
11 Transport of cryptotanshinone, a major active triterpenoid in Salvia miltiorrhiza Bunge widely used in the treatment of stroke and Alzheimer's disease, across the blood-brain barrier. Curr Drug Metab 2007 0.98
12 Insights into the structure, function, and regulation of human cytochrome P450 1A2. Curr Drug Metab 2009 0.96
13 Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus. Br J Clin Pharmacol 2006 0.96
14 Genetic polymorphisms of cytochrome P450 2B6 gene in Han Chinese. Eur J Pharm Sci 2006 0.95
15 ADME properties of herbal medicines in humans: evidence, challenges and strategies. Curr Pharm Des 2011 0.91
16 Inhibition of ErbB-2 and ErbB-3 expression by quercetin prevents transforming growth factor alpha (TGF-alpha)- and epidermal growth factor (EGF)-induced human PC-3 prostate cancer cell proliferation. Int J Oncol 2003 0.91
17 Topotecan is a substrate for multidrug resistance associated protein 4. Curr Drug Metab 2006 0.90
18 Antitumor activity and underlying mechanisms of ganopoly, the refined polysaccharides extracted from Ganoderma lucidum, in mice. Immunol Invest 2005 0.90
19 A pharmacogenetic study of pregnane X receptor (NR1I2) in Han Chinese. Curr Drug Metab 2007 0.89
20 Relationship between genotype and enzyme activity of glutathione S-transferases M1 and P1 in Chinese. Eur J Pharm Sci 2006 0.88
21 A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor. J Pharmacol Exp Ther 2006 0.88
22 Intra- and inter-ethnic differences in the allele frequencies of cytochrome P450 2B6 gene in Chinese. Pharm Res 2006 0.87
23 Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4. Ther Clin Risk Manag 2005 0.87
24 Transport of thalidomide by the human intestinal caco-2 monolayers. Eur J Drug Metab Pharmacokinet 2005 0.85
25 Transport of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide by human intestinal Caco-2 cells. Eur J Pharm Sci 2005 0.85
26 Small interfering RNA-mediated silencing of cytochrome P450 3A4 gene. Drug Metab Dispos 2006 0.84
27 Effects of water-soluble Ganoderma lucidum polysaccharides on the immune functions of patients with advanced lung cancer. J Med Food 2005 0.84
28 St. John's Wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats. Pharm Res 2005 0.83
29 The very C-terminus of protein kinase Cepsilon is critical for the full catalytic competence but its hydrophobic motif is dispensable for the interaction with 3-phosphoinositide-dependent kinase-1. Cell Signal 2005 0.83
30 Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in the rat. J Chromatogr B Analyt Technol Biomed Life Sci 2005 0.83
31 Loading 3-deazaneplanocin A into pegylated unilamellar liposomes by forming transient phenylboronic acid-drug complex and its pharmacokinetic features in Sprague-Dawley rats. Eur J Pharm Biopharm 2011 0.83
32 Tanshinone IIB, a primary active constituent from Salvia miltiorrhza, exhibits neuro-protective activity in experimentally stroked rats. Neurosci Lett 2007 0.83
33 Ganoderma lucidum polysaccharide fractions accelerate healing of acetic acid-induced ulcers in rats. J Med Food 2004 0.83
34 Prediction of deleterious non-synonymous single-nucleotide polymorphisms of human uridine diphosphate glucuronosyltransferase genes. AAPS J 2009 0.83
35 Simultaneous determination of irinotecan (CPT-11) and SN-38 in tissue culture media and cancer cells by high performance liquid chromatography: application to cellular metabolism and accumulation studies. J Chromatogr B Analyt Technol Biomed Life Sci 2007 0.83
36 Development of stealth liposome coencapsulating doxorubicin and fluoxetine. J Liposome Res 2011 0.81
37 Is a standard fixed dose of mycophenolate mofetil ideal for all patients? Nephrol Dial Transplant 2007 0.81
38 Predicting pharmacokinetic herb-drug interactions. Drug Metabol Drug Interact 2004 0.81
39 Induction of propranolol metabolism by Ginkgo biloba extract EGb 761 in rats. Curr Drug Metab 2006 0.81
40 The very C-terminus of PRK1/PKN is essential for its activation by RhoA and downstream signaling. Cell Signal 2006 0.80
41 Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide. Curr Drug Metab 2006 0.80
42 Novel agents that potentially inhibit irinotecan-induced diarrhea. Curr Med Chem 2005 0.79
43 Determination of thalidomide by high performance liquid chromatography: plasma pharmacokinetic studies in the rat. J Pharm Biomed Anal 2005 0.79
44 Role of P-glycoprotein in limiting the brain penetration of glabridin, an active isoflavan from the root of Glycyrrhiza glabra. Pharm Res 2007 0.79
45 A randomized, double-blind and placebo-controlled study of a Ganoderma lucidum polysaccharide extract in neurasthenia. J Med Food 2005 0.79
46 Effect of 5-fluorouracil on the anticoagulant activity and the pharmacokinetics of warfarin enantiomers in rats. Eur J Pharm Sci 2002 0.79
47 Enantioseparation of warfarin and its metabolites by capillary zone electrophoresis. Electrophoresis 2003 0.78
48 Effect of omeprazole on the anticoagulant activity and the pharmacokinetics of warfarin enantiomers in rats. Eur J Pharm Sci 2003 0.78
49 Quantification of 3-deazaneplanocin A, a novel epigenetic anticancer agent, in rat biosamples by hydrophilic interaction liquid chromatography-tandem mass spectrometric detection. J Chromatogr B Analyt Technol Biomed Life Sci 2010 0.78
50 A mechanistic study on altered pharmacokinetics of irinotecan by St. John's wort. Curr Drug Metab 2007 0.78
51 Evidence for dissolution rate-limited absorption of COL-3, a matrix metalloproteinase inhibitor, leading to the irregular absorption profile in rats after oral administration. Pharm Res 2002 0.78
52 Significant intestinal excretion, one source of variability in pharmacokinetics of COL-3, a chemically modified tetracycline. Pharm Res 2005 0.77
53 Role of P-glycoprotein in the intestinal absorption of glabridin, an active flavonoid from the root of Glycyrrhiza glabra. Drug Metab Dispos 2007 0.77
54 Simple reversed-phase ion-pair liquid chromatography assay for the simultaneous determination of mycophenolic acid and its glucuronide metabolite in human plasma and urine. J Chromatogr B Analyt Technol Biomed Life Sci 2004 0.77
55 Pharmacokinetics of recombinant human endostatin in rats. Curr Drug Metab 2006 0.77
56 Mechanism-based enterohepatic circulation model of mycophenolic acid and its glucuronide metabolite: assessment of impact of cyclosporine dose in Asian renal transplant patients. J Clin Pharmacol 2009 0.76
57 Effect of coenzyme Q10 on warfarin hydroxylation in rat and human liver microsomes. Curr Drug Metab 2005 0.75
58 Chiral CE separation of warfarin in albumin containing samples. J Pharm Biomed Anal 2002 0.75
59 Alteration of the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, due to acute gastrointestinal toxicity of doxorubicin. Pharm Res 2005 0.75
60 Estimation and comparison of carbamazepine population pharmacokinetics using dried blood spot and plasma concentrations from people with epilepsy: the clinical implication. J Clin Pharmacol 2013 0.75
61 Reversed-phase liquid chromatography method to determine COL-3, a matrix metalloproteinase inhibitor, in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci 2004 0.75
62 Developing a nomogram for dose individualization of phenytoin in Asian pediatric patients derived from population pharmacokinetic modeling of saturable pharmacokinetic profiles of the drug. Ther Drug Monit 2013 0.75
63 Effect of omeprazole on the hydroxylation of warfarin enantiomers in human: in-vitro studies with liver microsomes and cDNA-expressed cytochrome P450 isozymes. Curr Drug Metab 2005 0.75
64 Simultaneous and rapid quantitation of benazepril and benazeprilat in human plasma by high performance liquid chromatography with ultraviolet detection. J Pharm Biomed Anal 2007 0.75
65 Simple reversed-phase liquid chromatographic assay for simultaneous quantification of free mycophenolic acid and its glucuronide metabolite in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2006 0.75
66 Structural identification of a new acetildenafil analogue from pre-mixed bulk powder intended as a dietary supplement. Food Addit Contam 2006 0.75